- Trial phase
- Approved
- Time to market
- Already approved and marketed. Next-generation 25-valent pediatric vaccine is in Phase 3 (started May 2026); 35-valent adult candidate expected to enter clinical development by end of 2026, with potential approval likely several years away.
- Why 4/10
- Prevnar 20 is already FDA-approved and commercially marketed for both adults and pediatrics with no pending PDUFA or pivotal readout for the currently marketed product. The next catalysts are Phase 3 readouts for the 25-valent pediatric successor (25vPnC, started May 2026) and clinical entry of the 35-valent adult candidate, both >12 months from binary outcome. At ~10% of Pfizer's total revenue, Prevnar is a major product but not a single-asset binary for a $170B diversified pharma.
Watch for Phase 3 data readouts from Pfizer's 25-valent pediatric pneumococcal vaccine (25vPnC) and the clinical development start of the 35-valent adult candidate, both expected within the next 12-18 months. Near-term, monitor quarterly Prevnar sales trends for market share shifts against Merck's Capvaxive and Vaxcyte's VAX-31, which posted positive Phase 3 results in October 2026.
Price Chart
Executive Summary
Prevnar is Pfizer's blockbuster pneumococcal vaccine franchise, anchored by Prevnar 20 (PCV20), which is FDA-approved for both adults (2021) and children (2023). The franchise generated $6.49 billion in 2025, making it the world's top-selling vaccine portfolio, though Q3 2026 sales declined 10% year-over-year amid competition from Merck's Capvaxive (PCV21, approved 2024) and the threat of Vaxcyte's VAX-31, which posted positive Phase 3 results in October 2026. Pfizer is defending the franchise with a 25-valent pediatric vaccine now in Phase 3 and a 35-valent adult candidate expected to enter clinical development by end of 2026. As an already-approved, commercialized product at a diversified pharma giant, Prevnar has no near-term binary regulatory catalyst.
How It Works
Prevnar is a vaccine that trains the immune system to recognize and fight Streptococcus pneumoniae bacteria. It works by presenting pieces of the bacterial capsule (polysaccharides) linked to a carrier protein, which triggers the body to produce antibodies against up to 20 different strains (serotypes) of the bacteria. This prevents infections like pneumonia, meningitis, and bloodstream infections caused by these bacteria.
Trial Status
Prevnar 20 is FDA-approved and commercially marketed for adults (June 2021) and pediatrics (April 2023). Pfizer's next-gen 25-valent pediatric vaccine (25vPnC/PF-07872412) advanced to Phase 3 in May 2026 after strong Phase 2 data. A 35-valent adult candidate is planned for clinical entry by end of 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 data readouts for 25-valent pediatric pneumococcal vaccine (25vPnC, PF-07872412)
- Clinical development start for 35-valent adult pneumococcal vaccine candidate (expected by end of 2026)
- Quarterly Prevnar family sales trends and market share vs Merck's Capvaxive and Vaxcyte's VAX-31
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report